Evidence map›Paper›PMID 40820591›Full record

ArticleAdvanced healthcare materials2026

Novel 3D-Printed Biophotonic Scaffold Displaying Luminescence under Near-Infrared Light for Photopharmacological Activation and Biological Signaling Compound Release.

Sonya Ghanavati, Ekin Opar, Virginia Alessandra Gobbo, Carlo Matera, Fabio Riefolo, Rossella Castagna, Julien Colombelli, Andrew Draganski, Joshua Baggott, Mika Lastusaari and 3 more

Abstract read
In one paragraph

Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sonya GhanavatiFaculty of Medicine and Health Technology, Tampere University, Korkeakoulunkatu 3, Tampere, 33720, Finland.ORCID 0000-0001-5866-5054
Ekin OparInstitute for Bioengineering of Catalonia (IBEC), The Barcelona Institute for Science and Technology (BIST), Carrer de Baldiri Reixac 10, Barcelona, 08028, Spain.ORCID 0000-0002-1247-281X
Virginia Alessandra GobboFaculty of Medicine and Health Technology, Tampere University, Korkeakoulunkatu 3, Tampere, 33720, Finland.ORCID 0000-0001-6145-4047
Carlo MateraInstitute for Bioengineering of Catalonia (IBEC), The Barcelona Institute for Science and Technology (BIST), Carrer de Baldiri Reixac 10, Barcelona, 08028, Spain.ORCID 0000-0001-6939-3859
Fabio RiefoloInstitute for Bioengineering of Catalonia (IBEC), The Barcelona Institute for Science and Technology (BIST), Carrer de Baldiri Reixac 10, Barcelona, 08028, Spain.ORCID 0000-0002-6762-2619
Rossella CastagnaInstitute for Bioengineering of Catalonia (IBEC), The Barcelona Institute for Science and Technology (BIST), Carrer de Baldiri Reixac 10, Barcelona, 08028, Spain.ORCID 0000-0002-9284-3165
Julien ColombelliInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute for Science and Technology (BIST), c. Baldiri Reixac, 10, Barcelona, 08028, Spain.ORCID 0000-0002-2784-4276
Andrew DraganskiZylö Therapeutics, 105A Ben Hamby Dr, Greenville, SC, 29615, USA.
Joshua BaggottDepartment of Chemistry, University of Turku, Turku, FI-20014, Finland.
Mika LastusaariDepartment of Chemistry, University of Turku, Turku, FI-20014, Finland.ORCID 0000-0003-1872-0391
Pau GorostizaInstitute for Bioengineering of Catalonia (IBEC), The Barcelona Institute for Science and Technology (BIST), Carrer de Baldiri Reixac 10, Barcelona, 08028, Spain.ORCID 0000-0002-7268-5577
Laeticia PetitPhotonics Laboratory, Tampere University, Korkeakoulunkatu 3, Tampere, 33720, Finland.ORCID 0000-0002-1673-8996
Jonathan MasseraFaculty of Medicine and Health Technology, Tampere University, Korkeakoulunkatu 3, Tampere, 33720, Finland.ORCID 0000-0002-1099-8420

Funding

Academy of Finland 361159BEST Postdoctoral FellowshipEuropean CommissionEuropean Union's Horizon 2020 programme 101016787FPI fellowship PRE2020-092901H2020 Excellent Science 101130883H2020's Marie Sklowdoska-Curie Actions COFUND scheme 712754Horizon 2020 Framework Programme 945539;101016787project DEEPRED PID2019-111493RB-I00project EPILLUM PID2022- 142609OB-I00Severo Ochoa Programme SEV-2014-0425
6 · The paper itself

Abstract

Despite significant efforts in developing novel biomaterials to regenerate tissue, only a few of them have successfully reached clinical use. It has become clear that the next generation of biomaterials must be multifunctional. Smart biomaterials can respond to environmental or external stimuli, interact in a spatial-temporal manner, and trigger specific tissue/organism responses. In this study, the fabrication of novel 3D-printed and bioresorbable scaffolds, with embedded crystals that can convert near-infrared (NIR) light into visible light, is presented. It is demonstrated that these biophotonic scaffolds are not only bioactive and bioresorbable, but can also be promising as a platform for the controlled release or activation of photoactivated drugs locally and on demand, under illumination. The scaffolds are analyzed based on their up-conversion spectroscopic properties and their chemical stability in simulated body fluid. Furthermore, it is demonstrated that the up-conversion properties of the scaffolds are sufficient to release the signaling molecule nitric oxide (NO) and to photoisomerize the muscarinic ligand Phthalimide-Azo-Iperoxo (PAI), in a controlled manner, upon NIR light stimulus. Finally, to assess their biocompatibility for potential implantation, a preliminary study is conducted with human adipose stem cells cultured in contact with scaffolds. Live/dead assays, morphological analysis, CyQUANT analysis, and ion release measurements confirm that, despite some release of the upconverter crystals, the biophotonic materia and its dissolution by-products, are biocompatible. These findings highlight the potential of these bioresorbable biophotonic scaffolds for localized drug release in response to NIR light stimuli.

Indexed as

Infrared RaysPrinting, Three-DimensionalTissue ScaffoldsBiocompatible MaterialsDrug LiberationHumansLuminescenceNitric OxideBiocompatible MaterialsNitric Oxidedrug targetingimplantsluminescencenitric oxideoptopharmacologyphotopharmacologyphototherapeutic windowupconversion

Identifiers

PMID40820591
PMCPMC12927531

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.